Chiral Quest serves the global pharmaceutical industry with custom contract chemical development and manufacturing   services, from preclinical development to commercial supply. We have a state-of-the-art R&D laboratory, equipped with modern analytical instruments, as well as a first class manufacturing facility.  Chiral Quest has successfully developed more than 400 intermediates for Active Pharmaceutical Ingredients.  Ranging from preclinical to phase III, with four intermediates being supplied for API’s approved by the FDA.We manufacture technology advantaged products from grams to metric ton scale.

Generic Drug Intermediates
Chiral Quest’s key technologies for asymmetric hydrogenation have been applied to innovative routes for the manufacture of generic drugs intermediates, on metric ton scale.  For example, intermediates for Sitagliptin, Duloxetine, Aprepitant, Sacubitril and Lifesistat.

Technology Innovative Routes for Two API's

1. Sitagliptlin Intermediates
Sitagliptin is an oral anti-hyperglycemic of the dipeptidyl peptidase-4(DPP-4) inhibitor class to treat diabetes mellitus type 2.  By preventing GLP-1 and GIP inactivation, it is able to increase the secretion of insulin and suppress the release of glucagon by the pancreas, this drives blood glucose levels towards normal. Sitagliptin is a blockbuster drug with sales in excess of $6 Billion per year.

2. Duloxetine Intermediates
Duloxetine is a 5-serotonin and norepinephrine re-uptake inhibitors (SBRIs), effective for major depressive disorder and generalized anxiety disorder (GAD). With the dramatic increase in pressures of modern society, depressive disorder has become a common disease in our life.  The market for this type of drug will grow significantly.

2. Sacubitril Intermediates
Sacubitril is a neprilysin inhibitor, one part of ENTRESTO, indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction ENTRESTO will be a blockbuster drug in near future.


Home > About > Business